Indivior Added to S&P SmallCap 600, Enhancing Visibility

Indivior ( (INDV) ) has shared an update.

On December 22, 2025, Indivior PLC announced that its ordinary shares were included in the S&P SmallCap 600 index, aligning its capital markets profile more closely with its U.S.-focused business and signaling that it meets key criteria for liquidity and financial viability in the small-cap segment. Management highlighted the move as a significant milestone that supports its strategy to grow SUBLOCADE, its leading long-acting injectable treatment for moderate to severe opioid use disorder, under a simplified operating model, which could enhance visibility among investors and potentially bolster its competitive position in the addiction-treatment market.

The most recent analyst rating on (INDV) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.

Spark’s Take on INDV Stock

According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.

Indivior’s overall stock score reflects strong technical momentum and positive earnings call sentiment, offset by financial stability concerns due to negative equity and high leverage. The stock’s valuation is relatively high, which may deter value investors.

To see Spark’s full report on INDV stock, click here.

More about Indivior

Indivior PLC is a pharmaceuticals company focused on developing medicines to treat opioid use disorder, aiming to transform it from a human crisis into a recognized and treated chronic disease. Building on its portfolio of opioid use disorder treatments, the company is expanding a pipeline of product candidates to strengthen its position in this therapeutic category, with a particular emphasis on access to evidence-based treatment.

Average Trading Volume: 2,501,076

Technical Sentiment Signal: Buy

Current Market Cap: $4.4B

See more data about INDV stock on TipRanks’ Stock Analysis page.